Skip to main content

Health

GSK PLC GSK View profile

GSK expects pivotal GIST data in 2027 as Japan grants velzatinib orphan status

DNA Genotyping and Sequencing. Technician prepares for a viral whole-genome sequencing experiment at the Cancer Genomics Research Laboratory, part of the National Cancer Institute's Division of Cancer Epidemiology and Genetics (DCEG). — Credit: National Cancer Institute by Unsplash
National Cancer Institute by Unsplash

GSK, the FTSE 100 drugmaker, expects data from its second-line phase III trial of velzatinib in the second half of 2027, after Japan granted the drug orphan drug designation.

Enrolment in that trial is tracking ahead of schedule, the company said.

Velzatinib is a KIT inhibitor, a drug that blocks a protein driving tumour growth, designed for gastrointestinal stromal tumour (GIST), a rare cancer that usually arises in the stomach or small intestine.

Orphan drug designation, awarded here by Japan's health ministry, is a status for medicines that treat rare diseases.

It was supported by data from the ongoing phase I/Ib StrateGIST 1 trial, which showed promising anti-tumour activity and tolerability.

Velzatinib already holds US Food and Drug Administration Fast Track designation, plus orphan designation in the US and the European Union.

GSK is accelerating development, with phase III trials under way in first- and second-line advanced or metastatic GIST.

A phase II trial, StrateGIST J, is also running in Japan in patients whose disease has progressed or who cannot tolerate available treatments.

Seven abstracts will be presented at the Connective Tissue Oncology Society annual meeting in Seoul, which runs from 18 to 21 November.

They cover clinical analyses by KIT mutation in first- and second-line GIST, preclinical work on mutation coverage and translational biomarkers.

The market

Between 80,000 and 120,000 people are diagnosed with GIST worldwide each year.

About 80% of cases are driven by mutations in the KIT gene.

About 90% of patients treated in first line develop new KIT mutations that typically lead to relapse.

GSK says no approved tyrosine kinase inhibitor covers the full range of clinically relevant primary and secondary KIT mutations.

Velzatinib is designed to target all clinically relevant primary and key secondary KIT mutations.

Japan has one of the highest rates of GIST in the world, at about 4 cases per 100,000 people.